RANZCO’s golden jubilee

The Royal Australian and New Zealand College of Ophthalmology’s (RANZCO’s) 50th Annual Scientific Congress, and associated parallel conferences for Australasian...

VIP treatment for corneal transplants

A new study in The American Journal of Pathology reports for the first time that the injection of neuropeptide vasoactive intestinal peptide (VIP) directly...

Post-op adjustable GDD

Three patients at Manchester Royal Eye Hospital (MREH) are the first in the UK to test a new fully-adjustable surgical implant to drain excess eye fluid...

Open tech standards for better healthcare

In a move which significantly improves the ability for healthcare data to be shared between platforms and could keep healthcare costs down, Google, Amazon,...

NASA’s new vision devices

US company Web Vision Technologies has been awarded a grant to finalise the development of two new devices for NASA designed to monitor the vision health...

Personalising glaucoma

Personalised medicine, moving away from a one-size-fits-all approach, is a big thing in today’s British National Health Service and this can make a big...

Global trends in retina

According to the American Society of Retina Specialists’ (ASRS’s) 2018 Global Trends in Retina survey, a majority of respondents in all regions said they...

Targeted therapy for eye cancer?

Light-activated AU-011 has the potential to be the first targeted therapy for the primary treatment of ocular melanoma, said Clinical Assistant Professor...

Bottom Banner Advert